Theraly Fibrosis

Risk score

57
Large logo of Theraly Fibrosis

Headquarters

Flag of United States of AmericaUnited States of America

Theraly is a company at the preclinical stage with a goal to create innovative therapies for different types of fibrotic diseases such as chronic pancreatitis, systemic sclerosis, and NASH. Their primary candidate, TLY012, specifically targets myofibroblasts, which are believed to be the crucial source of fibrosis, a condition that impacts various tissues.